Trends of thrombo-inflammation biomarkers after Tocilizumab predict treatment failure better than scores in patients with severe SARS-CoV2 related respiratory failure.

Masotti, Luca; Cioni, Elisa; Grifoni, Elisa; Cei, Francesco; Tarquini, Roberto

Masotti, Luca; Cioni, Elisa; Grifoni, Elisa; Cei, Francesco; Tarquini, Roberto.

Masotti L; Internal Medicine II, San Giuseppe Hospital, Empoli, Italy. Electronic address: luca.masotti@tin.it.
Cioni E; Internal Medicine II, San Giuseppe Hospital, Empoli, Italy.
Grifoni E; Internal Medicine II, San Giuseppe Hospital, Empoli, Italy.
Cei F; Internal Medicine I, San Giuseppe Hospital, Empoli, Italy.
Tarquini R; Internal Medicine I, San Giuseppe Hospital, Empoli, Italy.

Eur J Intern Med ; 103: 111-112, 2022 09.

Article in English | MEDLINE | ID: covidwho-1944882

Subject(s)

COVID-19 Drug Treatment; Respiratory Insufficiency; Antibodies, Monoclonal, Humanized; Biomarkers; Humans; Inflammation; RNA, Viral; SARS-CoV-2; Treatment Failure

Keywords

CERRAHPASA score; COVID-19; Prognosis; Respiratory failure; SARS-CoV-2; Tocilizumab

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Respiratory Insufficiency / COVID-19 Drug Treatment Type of study: Prognostic study Limits: Humans Language: English Journal: Eur J Intern Med Journal subject: Internal Medicine Year: 2022 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google